RecruitingNCT06780475
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
15 participants
Start Date
May 27, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Patients \>= 18 years old;
- Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
- Informed for the study and no-opposed for participation;
- Affiliated with a social security scheme or in an equivalent situation.
Exclusion Criteria4
- Patients ongoing another interventional clinical trial;
- Patients under guardianship or trusteeship;
- Pregnancy or breastfeed;
- Patients refusal.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06780475